Clinical Trials Logo

PTEN Hamartoma Tumor Syndrome clinical trials

View clinical trials related to PTEN Hamartoma Tumor Syndrome.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02991807 Completed - Clinical trials for PTEN Hamartoma Tumor Syndrome

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

Start date: June 12, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Phosphatase and TENsin homolog (PTEN) gene germline mutations are associated with a spectrum of clinical manifestations characterized by neurocognitive deficits, intellectual disability, autism symptomatology, skin lesions, macrocephaly, hamartomatous overgrowth of tissues, and an increased risk of cancers. Investigators are conducting research to evaluate the potential safety and efficacy of RAD001 (everolimus) in this patient population, and the potential neurocognitive benefits from treatment with RAD001 or placebo for a six month period. The investigators hope this trial will lead to a better understanding of PTEN and to new forms of treatment that may benefit children and adults with PTEN in the future.